Cephalosporins – Market, Trends and Forecasts
Cephalosporins are broad-spectrum antibiotics of the β-lactam family. It is an antibiotic which is used to treat various bacterial infections such as skin, UTI, Pneumonia, bronchitis, Meningitis, Gonorrhoea and much more. In the market, it is available in generic and branded type and dosage forms are capsules, tablets and intravenous injections.
According to Market Research Report, the global cephalosporins market was valued at USD 14.72 billion in 2022 and is expected to grow at a CAGR of USD 17.15 billion by 2028. Increasing number of respiratory illnesses and increase in Research and Development are fuelling the demand for cephalosporins globally.
Key global manufacturers of cephalosporins are Qilu Antibiotics, Union Chempharma, Shandong Ruiying Pioneer Pharmaceutical, and Lupin Pharmaceuticals.
Types of cephalosporins available according to market segment:
- 1. First generation cephalosporins: Cefazolin, cephalexin, and cefadroxil are best used for various bacterial infections such as Gram-positive/negative bacteria.
- 2. Second generation cephalosporins: Cefuroxime, cefoxitin, and cefaclor are second generation cephalosporins derived from the first generation cephalosporins, they perform broad-spectrum activities against gram-negative bacteria.
- 3. Third Generation cephalosporins: They are the most commonly prescribed group of cephalosporins, beta-lactam class of drugs. They are made up of semisynthetic analogs and various chemical substitutions on C7 acylamido chain, for e.g., ceftriaxone, cefotaxime, and ceftazidime.
- 4. Fourth Generation cephalosporins: Cefepime, cefpirome, and cefozopran are reserved for complicated infections and are used in combination to improve efficacy.
Opportunities available in the global cephalosporin market:
The global market offers significant opportunities for Cephalosporin API manufacturers in India and internationally in emerging markets, such as China, India, and Brazil. This is because of the increasing prevalence of infectious diseases and the rising demand for antibiotics. There is increasing need and demand for the development of novel cephalosporin formulations to treat specific infections and improve patient outcomes. The increasing penetration of generic cephalosporins in the market offers opportunities for manufacturers to expand their product portfolios. Generic cephalosporins are cost-effective and offer a wider range of treatment options for patients.
Global Cephalosporin Market Dynamics:
The global cephalosporin market is driven by increasing prevalence of infections, rising demand for cephalosporin antibiotics, growing public health spending, and rising number of biologics and biosimilars. On the other hand, stringent regulatory framework, high cost of research and development, and emergence of resistance to cephalosporin antibiotics are some of the factors that are expected to inhibit the global cephalosporin market’s growth.
Current market trends for cephalosporins:
The use of combination therapy with cephalosporins and other antibiotics is becoming increasingly popular in the treatment of complicated infections. Plus the indications for cephalosporins are being broadened to include more uses such as community-acquired pneumonia, uncomplicated urinary tract infections, and gonorrhea. Resistance to cephalosporins is increasing, particularly in Gram-negative bacteria and multi-drug resistant strains. This is causing some health care professionals to become more selective in the use of cephalosporins. The newer cephalosporins, such as cefepime and ceftaroline are becoming increasingly available and offer better coverage against Gram-negative pathogens. Additionally, generic cephalosporins are becoming increasingly available and offer a more cost-effective option for clinicians.
Scope for cephalosporins in the future market growth:
The future market growth for cephalosporin manufacturers in India and across the globe is expected to be positive. Cephalosporins are a popular class of antibiotics used to treat a wide range of infections and are expected to remain a top choice for treating infectious diseases in the future. The global cephalosporin market is projected to grow at a CAGR of 4.7% from 2020 to 2027, driven by increasing prevalence of infectious diseases, growing geriatric population and rising demand for generic drugs for antibiotic treatments. Additionally, increasing research and development activities related to novel cephalosporin molecules, as well as the rising incidence of antibiotic resistance, are expected to drive the growth of the cephalosporin market in the coming years.